Drugs in Dev. Gastroenterology
Phase II
France 
Lead Product(s) : SAR444336
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAR444336 is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colitis, Microscopic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 05, 2025
Lead Product(s) : SAR444336
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amlitelimab
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Celiac Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Amlitelimab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ordesekimab
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRV-015 (anti-interleukin-15) is the first investigational product to show both a reduction in gluten-induced symptoms and in markers of intestinal inflammation in a placebo-controlled trial in celiac subjects .
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Ordesekimab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRV-015
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
Details : PRV-015 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Celiac Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : PRV-015
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
Details : Lanreotide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Obstruction.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lanreotide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Obstruction.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 27, 2014
Lead Product(s) : Lanreotide Acetate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis
Details : Clonidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stomatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2011
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : E.Coli Heat-Labile Enterotoxin
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
Details : E.Coli Heat-Labile Enterotoxin is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diarrhea.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 12, 2010
Lead Product(s) : E.Coli Heat-Labile Enterotoxin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
